Clinical Trial

Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma

Study acronym: ARTEMIDE-HCC01
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This is a Phase III, randomised, open-label, sponsor-blinded, 3-arm, multicentre, global study assessing the efficacy and safety of rilvegostomig in combination with bevacizumab with or without tremelimumab compared to atezolizumab in combination with bevacizumab. This study will be conducted in participants with advanced HCC who are not amenable to curative therapy or locoregional therapy
Protocol Amendment History 2 changes
notable Trial sites expanded: 217 -> 220 locations 2026-06-12
notable Trial sites expanded: 204 -> 217 locations 2026-05-12
Trial Details
NCT Number NCT06921785
Lead Sponsor AstraZeneca
Conditions Hepatocellular Carcinoma
Enrollment 1,220 participants
Start Date 2025-05-06
Primary Completion 2029-03-16 (estimated)
Study Completion 2030-03-15 (estimated)
Updated on ClinicalTrials.gov 2026-07-14